Your browser doesn't support javascript.
Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.
Huang, Yuan-Bin; Li, Wei-Lin; Sun, Man; Duan, Xu; Wang, Yu-Tong; Zhang, Lu-Xin; Xin, Zi-Han; Yun, Zhi-Fei; Fan, Bo; Li, Xian-Cheng.
  • Huang YB; Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116000, China.
  • Li WL; Second Clinical College, Dalian Medical University, Dalian 116000, China.
  • Sun M; Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116000, China.
  • Duan X; First Clinical College, Dalian Medical University, Dalian 116000, China.
  • Wang YT; Department of Urology, Second Affiliated Hospital of Dalian Medical University, Dalian 116000, China.
  • Zhang LX; Second Clinical College, Dalian Medical University, Dalian 116000, China.
  • Xin ZH; First Clinical College, Dalian Medical University, Dalian 116000, China.
  • Yun ZF; First Clinical College, Dalian Medical University, Dalian 116000, China.
  • Fan B; Second Clinical College, Dalian Medical University, Dalian 116000, China.
  • Li XC; First Clinical College, Dalian Medical University, Dalian 116000, China.
Asian J Androl ; 2022 Jul 29.
Article in English | MEDLINE | ID: covidwho-2296703
ABSTRACT
Studies have investigated the effects of androgen deprivation therapy (ADT) use on the incidence and clinical outcomes of coronavirus disease 2019 (COVID-19); however, the results have been inconsistent. We searched the PubMed, Medline, Cochrane, Scopus, and Web of Science databases from inception to March 2022; 13 studies covering 84 003 prostate cancer (PCa) patients with or without ADT met the eligibility criteria and were included in the meta-analysis. We calculated the pooled risk ratios (RRs) with 95% confidence intervals (CIs) to explore the association between ADT use and the infection risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and severity of COVID-19. After synthesizing the evidence, the pooled RR in the SARS-CoV-2 positive group was equal to 1.17, and the SARS-CoV-2 positive risk in PCa patients using ADT was not significantly different from that in those not using ADT (P = 0.544). Moreover, no significant results concerning the beneficial effect of ADT on the rate of intensive care unit admission (RR = 1.04, P = 0.872) or death risk (RR = 1.23, P = 0.53) were found. However, PCa patients with a history of ADT use had a markedly higher COVID-19 hospitalization rate (RR = 1.31, P = 0.015) than those with no history of ADT use. These findings indicate that ADT use by PCa patients is associated with a high risk of hospitalization during infection with SARS-CoV-2. A large number of high quality studies are needed to confirm these results.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Reviews Language: English Journal subject: Reproductive Medicine / Urology Year: 2022 Document Type: Article Affiliation country: Aja202246

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Reviews Language: English Journal subject: Reproductive Medicine / Urology Year: 2022 Document Type: Article Affiliation country: Aja202246